Repository logo
 

The CXCL12/CXCR4 Signaling Pathway: A New Susceptibility Factor in Human Papillomavirus Pathogenesis

Published version
Peer-reviewed

Type

Article

Change log

Authors

Meuris, F 
Carthagena, L 
Jaracz-Ros, A 
Gaudin, F 
Cutolo, P 

Abstract

The productive human papillomavirus (HPV) life cycle is tightly linked to the differentiation and cycling of keratinocytes. Deregulation of these processes and stimulation of cell proliferation by the action of viral oncoproteins and host cell factors underlies HPV-mediated carcinogenesis. Severe HPV infections characterize the wart, hypogammaglobulinemia, infection, and myelokathexis (WHIM) immunodeficiency syndrome, which is caused by gain-of-function mutations in the CXCR4 receptor for the CXCL12 chemokine, one of which is CXCR41013. We investigated whether CXCR41013 interferes in the HPV18 life cycle in epithelial organotypic cultures. Expression of CXCR41013 promoted stabilization of HPV oncoproteins, thus disturbing cell cycle progression and proliferation at the expense of the ordered expression of the viral genes required for virus production. Conversely, blocking CXCR41013 function restored virus production and limited HPV-induced carcinogenesis. Thus, CXCR4 and its potential activation by genetic alterations in the course of the carcinogenic process can be considered as an important host factor for HPV carcinogenesis.

Description

Keywords

Animals, Blotting, Western, Cell Line, Cell Transformation, Viral, Chemokine CXCL12, Genetic Predisposition to Disease, Heterografts, Human papillomavirus 18, Keratinocytes, Mice, Mice, Nude, Papillomavirus Infections, Receptors, CXCR4, Signal Transduction, Skin Neoplasms

Journal Title

PLoS Pathogens

Conference Name

Journal ISSN

1553-7366
1553-7374

Volume Title

12

Publisher

Public Library of Science (PLoS)
Sponsorship
Medical Research Council (MC_PC_13050)
This work was supported by the Institut National de la Santé et de la Recherche Médicale (FM, LC, CD, AJR, FG, PC, FB), ERA-Net for Research Programmes on Rare Diseases (WHIMThernet 2011-E-RARE 013-01) (FM, FB) and Institut National du Cancer (Chemokine-HPV TRANSLA11-077) (FM, CD, FB). We acknowledge funding from the French Laboratory of Excellence project LERMIT (Investissements d’Avenir-ANR-10-LABX-0033-LERMIT) (FM, AJR, PC, FB) and fellowship (FM) from the Fondation ARC pour la recherche sur le cancer.